Sfoglia per Autore
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
2007 Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM.
Positive Selection and Transplantation of Autologous Highly Purified CD133+ Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging
2007 Isidori, A; Motta, M R; Tani, M; Terragna, C; Zinzani, P; Curti, A; Rizzi, S; Taioli, S; Giudice, V; D'Addio, A; Gugliotta, G; Conte, R; Baccarani, M; Lemoli, R. M.
Thyrosin kinase inhibitors: nilotinib
2008 Castagnetti F.; Palandri F.; Gugliotta G.; Poerio A.; Amabile M.; Soverini S.; Martinelli G.; Baccarani M.; Rosti G.
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.
2009 Rosti G; Palandri F; Castagnetti F; Breccia M; Levato L; Gugliotta G; Capucci A; Cedrone M; Fava C; Intermesoli T; Cambrin GR; Stagno F; Tiribelli M; Amabile M; Luatti S; Poerio A; Soverini S; Testoni N; Martinelli G; Alimena G; Pane F; Saglio G; Baccarani M; GIMEMA CML Working Party.
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
2009 Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G.
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations
2009 Soverini S; Poerio A; Vitale A; Gnani A; Colarossi S; Castagnetti F.; Iacobucci I; Lonetti A; Palandri F; Rosti G; Amabile M; Paolini S; Papayannidis C; Gugliotta G; Vignetti M; Mandelli F; Baccarani M; Foà R; Martinelli G
Response definitions and European Leukemianet Management recommendations.
2009 Baccarani M; Castagnetti F; Gugliotta G; Palandri F; Soverini S
Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure
2009 Palandri F; Castagnetti F; Soverini S; Poerio A; Gugliotta G; Luatti S; Amabile M; Martinelli G; Rosti G; Baccarani M.
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison.
2010 Rosti G; Castagnetti F; Gugliotta G; Palandri F; Martinelli G; Baccarani M.
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase.
2010 Palandri F; Castagnetti F; Iacobucci I; Martinelli G; Amabile M; Gugliotta G; Poerio A; Testoni N; Breccia M; Bocchia M; Crugnola M; Rege-Cambrin G; Martino B; Pierri I; Radaelli F; Specchia G; Pane F; Saglio G; Rosti G; Baccarani M
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib
2011 Soverini S; Gnani A; De Benedittis C; Castagnetti F; Gugliotta G; Iacobucci I; Palandri F; Rosti G; Testoni N; Luatti S; Marzocchi G; Baccarani M; Martinelli G
Imatinib in chronic myeloid leukemia elderly patients.
2011 Gugliotta G;Castagnetti F;Palandri F;Baccarani M;Rosti G
F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib
2011 Anthony A. Oyekunle;Fausto Castagnetti;Gabriele Gugliotta;Simona Soverini;Michele Baccarani;Gianantonio Rosti
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis.
2011 Marzocchi G.; Castagnetti F.; Luatti S.; Baldazzi C.; Stacchini M.; Gugliotta G.; Amabile M.; Specchia G.; Sessarego M.; Giussani U.; Valori L.; Discepoli G.; Montaldi A.; Santoro A.; Bonaldi L.; Giudici G.; Cianciulli A.M.; Giacobbi F.; Palandri F.; Pane F.; Saglio G.; Martinelli G.; Baccarani M.; Rosti G.; Testoni N.
Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies
2011 Soverini S.; Gnani A.; De Benedittis C.; Castagnetti F.; Gugliotta G.; Bochicchio MT.; Palandri F.; Arpinati M.; Bonifazi F.; Abruzzese E.; Sorà F.; Alimena G.; Pregno P.; Specchia G.; Russo D.; Pane F.; Saglio G.; Salvucci M.; Zaccaria A.; Poletti G.; Giannini B.; Iacobucci I.; Lonetti A.; Durante S.; Rosti G.; Baccarani M.; Martinelli G.
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party.
2011 Gugliotta G.; Castagnetti F.; Palandri F.; Breccia M.; Intermesoli T.; Capucci A.; Martino B.; Pregno P.; Rupoli S.; Ferrero D.; Gherlinzoni F.; Montefusco E.; Bocchia M.; Tiribelli M.; Pierri I.; Grifoni F.; Marzocchi G.; Amabile M.; Testoni N.; Martinelli G.; Alimena G.; Pane F.; Saglio G.; Baccarani M.; Rosti G.
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications
2012 Simona Soverini, Caterina De Benedittis, Katerina Machova Polakova, Adela Brouckova, Fausto Castagnetti, Cristina Papayannidis, Gabriele Gugliotta, Francesca Palandri, Hana Klamova, Ilaria Iacobucci, Claudia Venturi, Federica Cattina, Paola Bresciani, Valeria Coluccio, Marzia Salvucci, Mario Tiribelli, Gianni Binotto, Tamara Intermesoli, Mario Luppi, Maria Teresa Bochicchio, Emanuela Ottaviani, Domenico Russo, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications
2012 Simona Soverini; Caterina De Benedittis; Katerina Machova Polakova; Adela Brouckova; Fausto Castagnetti; Cristina Papayannidis; Gabriele Gugliotta; Francesca Palandri; Hana Klamova; Ilaria Iacobucci; Claudia Venturi; Federica Cattina; Paola Bresciani; Valeria Coluccio; Marzia Salvucci; Mario Tiribelli; Gianni Binotto; Tamara Intermesoli; Mario Luppi; Maria Teresa Bochicchio; Emanuela Ottaviani; Domenico Russo; Gianantonio Rosti; Michele Baccarani; Giovanni Martinelli
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors
2012 S Soverini; C De Benedittis; F Cattina; A Broucková; K Machová Poláková; D Russo; A Gnani; I Iacobucci; MT Bochicchio; F Castagnetti; G Gugliotta; F Palandri; C Papayannidis; H Klamová; A Vitale; M Vignetti; R Foà; G Rosti; M Baccarani; G Martinelli
Frontline Treatment of Philadelphia Positive Chronic Myeloid Leukemia with Sequential Administration of Nilotinib 400 Mg Twice Daily and Imatinib 400 Mg Once Daily: a Phase 2 Multicentric Study
2012 F Castagnetti; G Rosti; M Breccia; F Stagno; A Gozzini; G Specchia; A Capucci; B Martino; G Rege Cambrin; L Luciano; E Abruzzese; M Bocchia; F Cavazzini; M Tiribelli; I Pierri; G Gugliotta; F Palandri; S Durante; S Soverini; N Testoni; F Pane; G Saglio; G Alimena; G Martinelli; M Baccarani
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. | Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Be...llo C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM. | 2007-01-01 | BRITISH JOURNAL OF HAEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Positive Selection and Transplantation of Autologous Highly Purified CD133+ Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging | Isidori, A; Motta, M R; Tani, M; Terragna, C; Zinzani, P; Curti, A; Rizzi, S; Taioli, S; Giudice,... V; D'Addio, A; Gugliotta, G; Conte, R; Baccarani, M; Lemoli, R. M. | 2007-01-01 | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | - | 1.01 Articolo in rivista | - |
| Thyrosin kinase inhibitors: nilotinib | Castagnetti F.; Palandri F.; Gugliotta G.; Poerio A.; Amabile M.; Soverini S.; Martinelli G.; Bac...carani M.; Rosti G. | 2008-01-01 | HEMATOLOGY MEETING REPORTS | - | 1.01 Articolo in rivista | - |
| Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. | Rosti G; Palandri F; Castagnetti F; Breccia M; Levato L; Gugliotta G; Capucci A; Cedrone M; Fava ...C; Intermesoli T; Cambrin GR; Stagno F; Tiribelli M; Amabile M; Luatti S; Poerio A; Soverini S; Testoni N; Martinelli G; Alimena G; Pane F; Saglio G; Baccarani M; GIMEMA CML Working Party. | 2009-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. | Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de... Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G. | 2009-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations | Soverini S; Poerio A; Vitale A; Gnani A; Colarossi S; Castagnetti F.; Iacobucci I; Lonetti A; Pal...andri F; Rosti G; Amabile M; Paolini S; Papayannidis C; Gugliotta G; Vignetti M; Mandelli F; Baccarani M; Foà R; Martinelli G | 2009-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| Response definitions and European Leukemianet Management recommendations. | Baccarani M; Castagnetti F; Gugliotta G; Palandri F; Soverini S | 2009-01-01 | BAILLIERE'S BEST PRACTICE IN CLINICAL HAEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure | Palandri F; Castagnetti F; Soverini S; Poerio A; Gugliotta G; Luatti S; Amabile M; Martinelli G; ...Rosti G; Baccarani M. | 2009-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison. | Rosti G; Castagnetti F; Gugliotta G; Palandri F; Martinelli G; Baccarani M. | 2010-01-01 | LEUKEMIA & LYMPHOMA | - | 1.01 Articolo in rivista | - |
| The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. | Palandri F; Castagnetti F; Iacobucci I; Martinelli G; Amabile M; Gugliotta G; Poerio A; Testoni N...; Breccia M; Bocchia M; Crugnola M; Rege-Cambrin G; Martino B; Pierri I; Radaelli F; Specchia G; Pane F; Saglio G; Rosti G; Baccarani M | 2010-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib | Soverini S; Gnani A; De Benedittis C; Castagnetti F; Gugliotta G; Iacobucci I; Palandri F; Rosti ...G; Testoni N; Luatti S; Marzocchi G; Baccarani M; Martinelli G | 2011-01-01 | LEUKEMIA RESEARCH | - | 1.01 Articolo in rivista | - |
| Imatinib in chronic myeloid leukemia elderly patients. | Gugliotta G;Castagnetti F;Palandri F;Baccarani M;Rosti G | 2011-01-01 | AGING | - | 1.01 Articolo in rivista | - |
| F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib | Anthony A. Oyekunle;Fausto Castagnetti;Gabriele Gugliotta;Simona Soverini;Michele Baccarani;Giana...ntonio Rosti | 2011-01-01 | LEUKEMIA RESEARCH | - | 1.01 Articolo in rivista | - |
| Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. | Marzocchi G.; Castagnetti F.; Luatti S.; Baldazzi C.; Stacchini M.; Gugliotta G.; Amabile M.; Spe...cchia G.; Sessarego M.; Giussani U.; Valori L.; Discepoli G.; Montaldi A.; Santoro A.; Bonaldi L.; Giudici G.; Cianciulli A.M.; Giacobbi F.; Palandri F.; Pane F.; Saglio G.; Martinelli G.; Baccarani M.; Rosti G.; Testoni N. | 2011-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies | Soverini S.; Gnani A.; De Benedittis C.; Castagnetti F.; Gugliotta G.; Bochicchio MT.; Palandri F....; Arpinati M.; Bonifazi F.; Abruzzese E.; Sorà F.; Alimena G.; Pregno P.; Specchia G.; Russo D.; Pane F.; Saglio G.; Salvucci M.; Zaccaria A.; Poletti G.; Giannini B.; Iacobucci I.; Lonetti A.; Durante S.; Rosti G.; Baccarani M.; Martinelli G. | 2011-01-01 | BLOOD | - | 4.02 Riassunto (Abstract) | - |
| Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. | Gugliotta G.; Castagnetti F.; Palandri F.; Breccia M.; Intermesoli T.; Capucci A.; Martino B.; Pr...egno P.; Rupoli S.; Ferrero D.; Gherlinzoni F.; Montefusco E.; Bocchia M.; Tiribelli M.; Pierri I.; Grifoni F.; Marzocchi G.; Amabile M.; Testoni N.; Martinelli G.; Alimena G.; Pane F.; Saglio G.; Baccarani M.; Rosti G. | 2011-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications | Simona Soverini, Caterina De Benedittis, Katerina Machova Polakova, Adela Brouckova, Fausto Casta...gnetti, Cristina Papayannidis, Gabriele Gugliotta, Francesca Palandri, Hana Klamova, Ilaria Iacobucci, Claudia Venturi, Federica Cattina, Paola Bresciani, Valeria Coluccio, Marzia Salvucci, Mario Tiribelli, Gianni Binotto, Tamara Intermesoli, Mario Luppi, Maria Teresa Bochicchio, Emanuela Ottaviani, Domenico Russo, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli | 2012-01-01 | BLOOD | - | 1.06 Abstract in rivista | - |
| Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications | Simona Soverini; Caterina De Benedittis; Katerina Machova Polakova; Adela Brouckova; Fausto Casta...gnetti; Cristina Papayannidis; Gabriele Gugliotta; Francesca Palandri; Hana Klamova; Ilaria Iacobucci; Claudia Venturi; Federica Cattina; Paola Bresciani; Valeria Coluccio; Marzia Salvucci; Mario Tiribelli; Gianni Binotto; Tamara Intermesoli; Mario Luppi; Maria Teresa Bochicchio; Emanuela Ottaviani; Domenico Russo; Gianantonio Rosti; Michele Baccarani; Giovanni Martinelli | 2012-01-01 | BLOOD | - | 4.02 Riassunto (Abstract) | - |
| High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors | S Soverini; C De Benedittis; F Cattina; A Broucková; K Machová Poláková; D Russo; A Gnani; I Iaco...bucci; MT Bochicchio; F Castagnetti; G Gugliotta; F Palandri; C Papayannidis; H Klamová; A Vitale; M Vignetti; R Foà; G Rosti; M Baccarani; G Martinelli | 2012-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| Frontline Treatment of Philadelphia Positive Chronic Myeloid Leukemia with Sequential Administration of Nilotinib 400 Mg Twice Daily and Imatinib 400 Mg Once Daily: a Phase 2 Multicentric Study | F Castagnetti; G Rosti; M Breccia; F Stagno; A Gozzini; G Specchia; A Capucci; B Martino; G Rege ...Cambrin; L Luciano; E Abruzzese; M Bocchia; F Cavazzini; M Tiribelli; I Pierri; G Gugliotta; F Palandri; S Durante; S Soverini; N Testoni; F Pane; G Saglio; G Alimena; G Martinelli; M Baccarani | 2012-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile